Welcome to our dedicated page for Beyondspring SEC filings (Ticker: BYSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Untangling BeyondSpring’s biotech disclosures can feel like decoding a lab manual. Every 10-K details the cash runway for Plinabulin’s Phase 3 trials, while 10-Q updates bury dose-limiting toxicity data deep in footnotes. If you’ve ever searched “BeyondSpring insider trading Form 4 transactions” or “how to read a BeyondSpring quarterly earnings report 10-Q filing,” you know the challenge.
Stock Titan resolves it. Our AI engine turns pages of technical language into concise highlights, giving you “BeyondSpring SEC filings explained simply” in minutes. Receive alerts on “BeyondSpring Form 4 insider transactions real-time,” track FDA-driven “BeyondSpring 8-K material events explained,” and dive into a “BeyondSpring annual report 10-K simplified” summary that calls out R&D spend, milestone payments, and going-concern disclosures. Whether you’re reviewing “BeyondSpring executive stock transactions Form 4,” requesting a “BeyondSpring earnings report filing analysis,” or comparing segment revenue shifts, our platform surfaces the numbers and context that matter.
Why focus on BeyondSpring? Drug-development costs, milestone-based licensing revenue, and equity stakes in SEED Therapeutics make each filing uniquely data-dense. Stock Titan’s expert layer flags where non-cash R&D credits affect margins, highlights trial-enrollment shifts that alter cash burn, and links proxy-statement tables—search “BeyondSpring proxy statement executive compensation”—directly to dilution scenarios. Real-time EDGAR feeds, AI-powered summaries, and clean navigation mean you spend less time scrolling and more time valuing BYSI’s oncology pipeline. Understanding BeyondSpring SEC documents with AI has never been this straightforward.
BeyondSpring (BYSI) reported insider transactions by Decheng Capital–affiliated funds. Decheng Capital China Life Sciences USD Fund III, L.P. reported sales of 107,361 ordinary shares on 10/13/2025 at a weighted average price of $1.70 (range $1.69–$1.75), 28,495 shares on 10/14/2025 at $1.65 (range $1.62–$1.70), and 17,960 shares on 10/15/2025 at $1.65 (range $1.60–$1.685). Following these trades, Fund III reported 1,650,204 shares indirectly held. Other reported indirect holdings were 1,617,409 shares by Fund II and 891,734 shares by the Global Healthcare Fund.
Decheng Capital affiliates and Dr. Xiangmin Cui reported insider sales of BeyondSpring Inc. (BYSI) ordinary shares across three trading dates. Fund III sold 7,507 shares on
BeyondSpring Inc. (BYSI): Decheng Capital-affiliated reporting persons disclosed open-market sales of ordinary shares. On 10/03, 600 shares were sold at $1.76 (weighted average range $1.73–$1.79); on 10/06, 17,500 shares at $1.78 (range $1.73–$1.7879); and on 10/07, 2,100 shares at $1.79 (range $1.74–$1.80). The filing is made by more than one reporting person, noted as Director and 10% Owner.
Following these transactions, indirect beneficial holdings were reported as 1,817,896 shares by Decheng Capital China Life Sciences USD Fund III, L.P., 1,617,409 shares by Decheng Capital China Life Sciences USD Fund II, L.P., and 891,734 shares by Decheng Capital Global Healthcare Fund (Master), LP.
Decheng Capital reporting persons, including funds managed by Dr. Xiangmin Cui, disclosed insider sales of 7,665 BeyondSpring Inc. (BYSI) ordinary shares across three days. The filings show 4,464 shares sold on 09/30/2025 at a weighted average price of about $1.81, 2,601 shares sold on 10/01/2025 at about $1.80, and 600 shares sold on 10/02/2025 at about $1.73. After the reported transactions, Decheng Capital China Life Sciences USD Fund III, L.P. is shown as beneficially owning approximately 1,838,096–1,841,297 shares (per line entries), while affiliated funds report holdings of 1,617,409 and 891,734 shares respectively. The footnotes state the prices are weighted averages within disclosed ranges and confirm the reporting chain through GP entities managed by Dr. Cui.
Decheng Capital entities disclosed multiple small sales of BeyondSpring Inc. (BYSI) ordinary shares in late September 2025. Fund III sold 1,800 shares on 09/25/2025 through 09/29/2025 in three reported transactions (700 at a weighted average $1.66, 600 at $1.68, 500 at $1.75), reducing Fund III's reported holdings to 1,845,761 shares after the last sale. Related Decheng entities report additional indirect holdings of 1,617,409 shares (Fund II) and 891,734 shares (Global Healthcare Master).
The filings identify Decheng Capital Management III (GP III) and Dr. Xiangmin (Cui) as manager/related parties and state that GP and Dr. Cui may be deemed beneficial owners of the funds' holdings but disclaim direct ownership except for pecuniary interest. The transactions are reported as sales with weighted average price ranges disclosed in footnotes.
Decheng Capital-related funds and manager Dr. Xiangmin Cui reported insider sales of BeyondSpring Inc. (BYSI) ordinary shares over three consecutive days in September 2025. The filings show Fund III sold 5,410 shares on 09/22/2025 at a weighted average price of $1.83, 4,106 shares on 09/23/2025 at $1.72, and 2,256 shares on 09/24/2025 at $1.68, for a total of 11,772 shares sold across the three transactions. After these sales, Fund III beneficially owned 1,847,561 shares. The Form 4 also discloses indirect holdings by affiliated vehicles: Fund II holds 1,617,409 shares and Decheng Capital Global Healthcare Fund (Master) holds 891,734 shares. The filings state the reported prices are weighted averages for multiple transactions within specified ranges and identify Decheng Capital management entities and Dr. Cui as the reporting persons.
Decheng Capital entities reported insider dispositions of BeyondSpring Inc. (BYSI) ordinary shares across three days in September 2025. Decheng Capital China Life Sciences USD Fund III sold 2,304 shares on 09/17/2025 at a weighted average price of $1.83, 5,307 shares on 09/18/2025 at $1.74, and 3,656 shares on 09/19/2025 at $1.79, totaling 11,267 shares sold and leaving Fund III with 1,859,333 shares. The filing also shows indirect holdings of 1,617,409 shares by Decheng Capital China Life Sciences USD Fund II and 891,734 shares by Decheng Capital Global Healthcare Fund (Master), LP. Footnotes explain weighted average pricing ranges and that GP entities and Dr. Xiangmin Cui may be deemed beneficial owners but disclaim direct ownership except for pecuniary interest.
Insider sales by Decheng-affiliated funds in BeyondSpring (BYSI) The filing shows Decheng Capital entities and Dr. Xiangmin Cui reported a series of open-market dispositions of BeyondSpring ordinary shares in mid-September 2025. Decheng Capital China Life Sciences USD Fund III, L.P. sold a total of 4,110 shares across trades on 09/12/2025, 09/15/2025 and 09/16/2025 at weighted-average prices reported as $1.85, $1.84 and $1.88 respectively. After those sales, Fund III’s reported beneficial ownership was 1,870,600 shares. The filing also reports indirect beneficial ownership of 1,617,409 shares by Decheng Capital China Life Sciences USD Fund II, L.P. and 891,734 shares by Decheng Capital Global Healthcare Fund (Master), LP. Signatures indicate Dr. Xiangmin Cui as manager executing the filing on behalf of the Decheng entities on 09/16/2025.
BeyondSpring Inc. held its 2025 annual meeting of shareholders on September 15, 2025. Shareholders representing 21,852,265 ordinary shares, or approximately 54.19% of the 40,322,320 outstanding shares entitled to vote as of the July 25, 2025 record date, were present or represented by proxy. Shareholders ratified the appointment of CBIZ CPAs P.C. as the companys independent registered public accounting firm for the fiscal year ending December 31, 2025, with 21,831,390 votes in favor, 14,265 against, and 6,610 abstentions.
FAQ
What is the current stock price of Beyondspring (BYSI)?
What is the market cap of Beyondspring (BYSI)?
